Medigus (NASDAQ:MDGS) announced a distribution agreement in Switzerland and Liechtenstein with ADMEDICS AG medical device distributor.
As quoted in the press release:
ADMEDICS AG will be required to purchase a minimum of EUR 1.8 million of Medigus Ultrasonic Surgical Endostapler (MUSE™) equipment over the course of the five-year agreement.
“The introduction of a minimally invasive treatment option such as MUSE™ into Switzerland and Liechtenstein will greatly benefit gastroesophageal reflux disease (GERD) patients,” said Hans Jäggi, President, ADMEDICS AG. “MUSE™ addresses the unmet treatment need for patients who can no longer rely on drug therapy. This minimally invasive and more cost-effective option can benefit these patients, their doctors and the healthcare system at large.”
“GERD is a highly prevalent disease in Western countries[i], so we are excited to expand availability of MUSE™ to Switzerland and Liechtenstein, two development markets that will greatly benefit from it, ” said Chris Rowland, Chief Executive Officer of Medigus. “We are pleased to have ADMEDICS AG as our partner, and our distribution agreement is an important milestone for expanding market access to our product.”